BTC USD price today drops to $66,000: Why Robert Kiyosaki bought more Bitcoin during crypto crash and said it will be better than gold?BTC USD Bitcoin investment strategy Robert Kiyosaki: Despite calling the crypto market a 'crash,' Rich Dad Poor Dad author Robert Kiyosaki ...
US Stocks | Wall Street ends sharply lower amid AI displacement fears and revived tariff angstA broad selloff sent all three major U.S. stock indexes more than 1% lower by the closing bell, as risk appetite was dampened by a combinat...
S&P 500, Dow Jones, Nasdaq crash at U.S Stock Market. Top gaining, losing stocks at Wall StreetU.S Stock Market today: On Wall Street, big losses hit companies under suspicion of getting undercut by AI-powered rivals. Investors have b...
Why did NVO stock crash over 14% today? Novo Nordisk’s weight-loss drug CagriSema misses trial goal against Eli Lilly’s TirzepatideNVO stock today: Novo Nordisk shares plummeted after its next-generation weight loss drug, CagriSema, failed to achieve non-inferiority in ...
Novo Nordisk's $475-billion rise and fall as Wegovy-era gains wiped outNovo Nordisk shares have fallen sharply. Their new obesity drug, CagriSema, did not meet expectations in trials. This setback affects futur...
Word of the day: ChaperoneChaperone meaning: The word chaperone has a rich history. It means a person who supervises younger individuals. This term comes from French...
NVO stock crashes 14%: Why Novo Nordisk shares are down today? 2026 sales forecast and Eli Lilly competition explainedNVO Novo Nordisk stock today: Novo Nordisk shares tumbled after the drugmaker forecast a sales and profit drop for 2026. This outlook comes...
Weight-loss treatment: How has obesity medicine market become battleground for pharma giants like Pfizer, AstraZeneca, Eli Lilly?Obesity, weight-loss medicines: Novo has been scrambling to keep pace in the obesity drug race it started, losing ground to rival Eli Lilly...
Novo Nordisk to test weight-loss drugs in broader range of obesity-linked conditionsNovo Nordisk is broadening its focus beyond obesity and diabetes by exploring the potential of its weight-loss drugs, including Wegovy, to ...
Is Novo Nordisk facing its “Nokia moment”? Stock tumbles to $50 from a year-high of $139 amid disruptive rivals and shifting market forcesNovo Nordisk’s stock has tumbled from record highs after slashing its 2025 outlook, as fierce competition, leadership changes, and legal ch...
US stocks drift higher as investors await Tehran's response to US strikesWall Street's main indexes opened subdued on Monday as investors awaited Iran's possible response to U.S. airstrikes on its nuclear facilit...
European shares dip at the open; Novo Nordisk jumpsEuropean stocks opened lower, mirroring last week's decline, with travel and media sectors lagging. Novo Nordisk rebounded after Friday's l...
What can a wonder drug maker and a phone maker have in common? Their fall from graceNovo Nordisk's reign as Europe's most valuable company is facing a challenge from US rival Eli Lilly. Lilly's weight-loss drug, Zepbound, i...
Dr Reddy’s, Sun, Cipla and Biocon look to recreate Ozempic magic in IndiaDoctors say patients come with specific queries regarding weight-loss drugs, which have become both the first preference and the last resor...